This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

David Cole, PhD
Collaboration Research Group Leader at Immunocore

Profile

Dr David Cole currently leads Collaboration Research at Immunocore, a privately funded biotech just outside of Oxford that is developing novel bispecific T cell engagers using engineered T cell receptor technology. Before moving to Immunocore in 2017, David spent a number of years in academia, completing his PhD at Oxford University in 2007, before setting up his own laboratory at Cardiff University in 2009. During his academic career, David used a variety of molecular approaches (X-ray crystallography, biophysics, protein engineering) to better understand the nature of T cell antigen recognition, which is governed by the interaction between the T cell receptor and peptide-human leukocyte antigen. In his current role at Immunocore, he is now applying this fundamental understanding of T cell receptors to help develop novel drugs to treat cancer.

Agenda Sessions

  • LIVE Moderated Panel Discussion and Q&A Including Audience Interaction with Speakers from On-Demand SESSION #5: BISPECIFIC ANTIBODIES: NEW APPROACHES AND CASE STUDIES - To prepare for this discussion/Q&A, attendees should view the presentations from Session #5 in the Watch On-Demand Sessions Tab prior to this session

    15:45
  • The Distinct Binding Footprints of Bispecific T cell Receptors (TCR) and TCR-mimic Antibodies Underpin pHLA Selectivity

    On Demand